Ver­tex ponies up $100M for CRISPR's gene edit­ing tech to de­vel­op new di­a­betes modal­i­ty

Ver­tex is pay­ing nine fig­ures to get its hands on CRISPR Ther­a­peu­tics’ gene edit­ing tech­nol­o­gy in a bid to make a third ap­proach for type 1 di­a­betes.

The biotech said Mon­day morn­ing that it is pay­ing $100 mil­lion up­front to nab non-ex­clu­sive rights to CRISPR Ther­a­peu­tics’ CRISPR/Cas9 gene edit­ing tech­nol­o­gy. The goal, ac­cord­ing to Ver­tex, is to move for­ward with pre­clin­i­cal de­vel­op­ment of a hy­poim­mune gene-edit­ed cell ther­a­py for type 1 di­a­betes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER